(Total Views: 1002)
Posted On: 10/11/2020 10:18:15 AM
Post# of 156826
My understanding is that they are requesting EUA based on interim data. But their trials are quite large and so their interim is like 400 plus patients.
Neither Lilly nor Regeneron's MABs are competition for us. They are neutralizing MABs and must be given early in the disease only. They are not immunomodulators. They do not prevent the cytokine storm. They prevent the virus from invading the cells, so they may prevent moderates from becoming severes, but there are currently very few doses available. There is still going to be a role for immunomodulators, like leronlimab.
That is my understanding and opinion only. I am not a doctor or scientist.
Neither Lilly nor Regeneron's MABs are competition for us. They are neutralizing MABs and must be given early in the disease only. They are not immunomodulators. They do not prevent the cytokine storm. They prevent the virus from invading the cells, so they may prevent moderates from becoming severes, but there are currently very few doses available. There is still going to be a role for immunomodulators, like leronlimab.
That is my understanding and opinion only. I am not a doctor or scientist.
(8)
(0)
